Search clinical trials for: BMS-986165 Dose 2

Total 1779 results

Bristol-Myers Squibb

Withdrawn

An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | Lung Cancer

Italy, Korea, Republic of, Turkey, Canada, Spain, Australia, Mexico, Taiwan, France, Germany, Switzerland, Greece, Japan, Austria, United States, Brazil, Czechia
Bristol-Myers Squibb

Completed

An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea (POETYK-PSO-3)

Psoriasis

China, Korea, Republic of, Taiwan
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis

Palmoplantar Psoriasis | Genital Psoriasis

United States, Germany, Spain, Italy, Poland, Argentina, Canada
Bristol-Myers Squibb

Active, not recruiting

Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis

Psoriasis

United States, France, Germany, Poland, United Kingdom
Pfizer

Completed

Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally

Fungal Infection

Netherlands
Mayo Clinic
Bristol-Myers Squibb

Recruiting

A Study of Deucravacitinib to Treat LPP and FFA

Lichen Planopilaris

United States
Bristol-Myers Squibb

Completed

An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

Taiwan, United States, Hungary, Argentina, Canada, Spain, Japan, Poland, Russian Federation, Korea, Republic of, Israel, Romania, Mexico, Australia, Brazil, Colombia, Germany
Bristol-Myers Squibb
Covance

Completed

Pharmacokinetics and Metabolism of [14C]BMS-986165 in Healthy Male Participants

Psoriasis

United States
Bristol-Myers Squibb

Recruiting

Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) (AURORA-HFpEF)

Heart Failure

United States, Spain, Canada, Italy, Poland
Ronald Levy
National Cancer Institute (NCI)

Active, not recruiting

TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas

Mantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | B-Cell Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma

United States
Bristol-Myers Squibb

Recruiting

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

Psoriatic Arthritis

Italy, United States, Australia, Argentina, Brazil, Czechia, France, Hungary, Mexico, Russian Federation, China, Poland, Finland, Colombia, United Kingdom, Bulgaria, Taiwan, Chile, Romania, Spain, Ireland
Bristol-Myers Squibb

Terminated

Single Ascending Dose and Multiple Ascending Dose Study in Healthy Participants and Proof of Mechanism Study in Patients With Ulcerative Colitis

Healthy Volunteers | Ulcerative Colitis

Australia, Georgia, Moldova, Republic of
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Recruiting

Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma

United States
Bristol-Myers Squibb
Cardioxyl Pharmaceuticals, Inc

Completed

A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers

Heart Failure
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting (ARTISTYK)

Psoriasis

United States, Puerto Rico
Bristol-Myers Squibb

Terminated

A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis

Colitis, Ulcerative

United States, Australia, Canada, Germany, Poland, Puerto Rico, United Kingdom, Netherlands
Bristol-Myers Squibb

Active, not recruiting

A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata

Alopecia Areata

Canada, France, Japan, Australia, United States, Poland
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety, Tolerability, and Drug Levels of MYK-224 Administered in Single and Multiple Doses in Healthy Adult Japanese Participants

Healthy Volunteers

United States
Medy-Tox

Completed

MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)

Lateral Canthal Lines | Glabellar Lines

United States, Russian Federation, Germany, Canada, Belgium, United Kingdom
Bristol-Myers Squibb

Terminated

An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease

Crohn's Disease | Granulomatous Colitis | Crohn's Enteritis | Granulomatous Enteritis

Canada, Germany, Taiwan, United States, Spain, Australia, Poland, Russian Federation, Japan, Korea, Republic of, Romania, Italy, United Kingdom, Belgium, Brazil, China, Czechia, France, Hungary, Ireland, Israel, Mexico, Netherlands, P... and more
Northwestern University
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Glioblastoma

United States
Boehringer Ingelheim

Completed

Bioequivalence Study of Two Strengths of Two Different Metformin Tablets Administered to Healthy Male and Female Subjects

Healthy
Sanofi Pasteur, a Sanofi Company

Completed

Safety of a Single Dose or Two Doses of Shenzhen Quadrivalent Influenza Vaccine

Influenza | Flu

China
Biogen

Terminated

Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease (TANGO)

Alzheimer's Disease

United States, Spain, Italy, Australia, France, Poland, Germany, Japan, Sweden
Bristol-Myers Squibb
Nitto Denko Corporation

Completed

Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4)

Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4)

Bulgaria, United States
University Medical Center Groningen

Completed

PD-L1 PET Imaging in Melanoma Patients

Melanoma

Netherlands
Bristol-Myers Squibb

Completed

A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects

Ischemic Stroke

United States
Beth Israel Deaconess Medical Center
Bristol-Myers Squibb

Recruiting

Evaluating the Safety and Efficacy of Deucravacitinib Compared to Placebo Hidradenitis Suppurativa (HS).

Hidradenitis Suppurativa

United States
Bristol-Myers Squibb

Completed

A Phase I Study of BMS-641988 in Japanese Patients With Castration Resistant Prostate Cancer

Prostate Cancer

Japan
Bristol-Myers Squibb

Completed

An Investigational Study of BMS-986165 in Participants With Normal Liver Function and Participants With Mild to Severe Liver Damage

Healthy Volunteers | Liver Dysfunction

Czechia, Hungary, Slovakia
Bristol-Myers Squibb

Completed

An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition.

Healthy Male Volunteers

United States
Bristol-Myers Squibb

Completed

Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy Subjects

Rheumatoid Arthritis

Australia
Bristol-Myers Squibb

Completed

An Investigational Study to Assess the Effect of a Light Meal and a High-Fat Meal on the Absorption of BMS-986205 in Healthy Participants

Healthy Volunteers

United States
Bristol-Myers Squibb
Nitto Denko Corporation

Completed

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Escalating Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ND-L02-s0201 Injection in Normal Healthy Subjects

Healthy

United States
Ablynx

Completed

Caplacizumab Single and Multiple Dose Study in Healthy Japanese and White Subjects.

Healthy Volunteers

United States
Loyola University
National Cancer Institute (NCI)

Active, not recruiting

Transfer of Genetically Engineered Lymphocytes in Melanoma Patients

Melanoma

United States
Bristol-Myers Squibb

Completed

The Effect of BMS-986142 on the Pharmacokinetics of a Combined Oral Contraceptive (OC) Containing Ethinyl Estradiol (EE) and Norethindrone Acetate (NET) in Healthy Female Subjects

Arthritis

United States
Bristol-Myers Squibb

Active, not recruiting

A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors

Advanced Solid Tumors

United States, Chile, Argentina, Belgium, Canada, Japan, Netherlands
Bristol-Myers Squibb

Recruiting

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission

Acute Myeloid Leukemia

Japan, United States
Aronora, Inc.

Completed

Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis

Thrombosis | End Stage Renal Disease

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Completed

Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells (CLIPA)

Leukemia | Leukemia, B-Cell, Chronic

United States
Bristol-Myers Squibb

Completed

A Study to Assess Relative Bioavailability of Branebrutinib, From a Tablet Formulation to the Capsule Formulation, the Effect of Food on the Bioavailability of Branebrutinib From a Tablet Formulation, and the Safety and Drug Levels of Branebrutinib From a Tablet Formulation in Healthy Participants

Healthy Volunteers

United States
Bristol-Myers Squibb

Completed

A Study of BMS-986195 in Healthy Male Subjects

Rheumatoid Arthritis

Netherlands
J2H Biotech

Completed

Phase 1 Study to Investigate Safety, Tolerability, PK/PD of J2H-1702 in Healthy Females

Non-alcoholic Steatohepatitis

Korea, Republic of
Bristol-Myers Squibb

Completed

A Study to Assess the Absorption of a Single Dose of BMS-986205 in Healthy Volunteers When Administered as a Crushed Tablet Orally or Crushed Tablet Suspension Via Nasogastric Tube, as Compared to a Tablet

Healthy Volunteers

United States
Acerus Pharmaceuticals Corporation

Completed

Efficacy and Safety of TBS-2 Testosterone Gel in Women With Acquired Female Orgasmic Disorder

Female Orgasmic Disorder

United States, Canada, Australia
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors

Advanced Cancer

Japan
Pharnext SA

Completed

Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT) (PLEO-CMT)

Charcot-Marie-Tooth Disease Type 1A

United States, United Kingdom, Belgium, Canada, France, Netherlands, Spain, Germany
Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.

Solid Tumors

United States, Australia, Spain, Germany, France, Switzerland, Netherlands, Canada, Belgium, Italy
Virginia Commonwealth University
Gilead Sciences

Withdrawn

Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL (RIVe-CLL/SLL)

Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | CLL | Refractory Small Lymphocytic Lymphoma | SLL | Relapsed CLL | Relapsed Chronic Lymphocytic Leukemia | Relapsed Small Lymphocytic Lymphoma

3

Subscribe